MaxCyte granted Legend Biotech a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in connection with the research, clinical development, and commercialization of cell-based therapeutic products.

In return, MaxCyte will be eligible to receive annual licensing fees and milestones from Legend Biotech during clinical development and, upon successful commercialization, is eligible to receive licensing fees and royalties on net sales of licensed products.

“We are looking forward to supporting Legend Biotech’s non-viral engineered cell therapy program as they expand their portfolio with new delivery modalities. Our global infrastructure allows us to provide Legend Biotech with technical, scientific, and regulatory support to advance its non-viral engineered therapeutic pipeline across all major regions,” said Maher Masoud, president and CEO of MaxCyte.

“MaxCyte’s clinical manufacturing platform, non-viral cell engineering technology, and regulatory expertise will support the development of our product pipeline across a wide variety of cell types and modalities,” added Ying Huang, PhD, CEO of Legend Biotech. “Our goal is to transform the treatment landscape by creating a broad portfolio of cell therapies to help strengthen patients’ immune systems and fight disease.”

Previous articleLeukemia Therapy Approach “Deletes” Affected Blood System While Transplanting Healthy Stem Cells
Next articleAdding Metabolism to Models of Bioprocessing